First author | Year | Country | Ethnicity | Cancer type | Sample size | Case | Controls | HWE (control) | |||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Case | Control | AA | AB | BB | AA | AB | BB | ||||||
rs2296241 | |||||||||||||
 Holt a | 2009 | USA | Caucasian | Prostate cancer | 692 | 705 | 166 | 356 | 170 | 151 | 371 | 183 | 0.147 |
 Holt b | 2009 | USA | African | Prostate cancer | 112 | 66 | 25 | 50 | 37 | 12 | 39 | 15 | 0.134 |
 Wu | 2017 | China | Asian | Lung cancer | 426 | 445 | 119 | 230 | 77 | 114 | 227 | 104 | 0.662 |
 Holick | 2007 | UK | Caucasian | Prostate cancer | 571 | 539 | 134 | 285 | 152 | 107 | 275 | 157 | 0.497 |
 McCullough | 2007 | USA | Caucasian | Breast cancer | 494 | 490 | 99 | 254 | 141 | 98 | 253 | 139 | 0.377 |
 Penna-Martinez PTC | 2012 | Germany | Caucasian | Thyroid carcinoma | 205 | 302 | 47 | 101 | 57 | 62 | 151 | 89 | 0.889 |
 Penna-Martinez FTC | 2012 | Germany | Caucasian | Thyroid carcinoma | 48 | 302 | 17 | 22 | 9 | 62 | 151 | 89 | 0.889 |
 Yang | 2017 | China | Asian | ESCC | 569 | 556 | 116 | 263 | 190 | 113 | 292 | 151 | 0.192 |
 Anderson | 2011 | Canada | Caucasian | Breast cancer | 1556 | 1630 | 330 | 777 | 449 | 371 | 791 | 468 | 0.294 |
 Oh | 2009 | Korea | Asian | Prostate cancer | 272 | 173 | 64(A%) | 36(B%) |  | 55.8(A%) | 44.2(B%) |  |  |
 Beuten | 2011 | USA | Caucasian | Prostate cancer | 609 | 348 | 48.4(A%) | 51.6(B%) |  | 47(A%) | 53(B%) |  |  |
 Beuten | 2011 | USA | Caucasian | Prostate cancer | 195 | 514 | 55.4(A%) | 44.6(B%) |  | 55.9(A%) | 44.1(B%) |  |  |
 Beuten | 2011 | USA | African | Prostate cancer | 82 | 109 | 54.9(A%) | 45.1(B%) |  | 49.7(A%) | 50.3(B%) |  |  |
rs4809957 | |||||||||||||
 Anderson | 2013 | Canada | Caucasian | Pancreas cancer | 627 | 1189 | 362 | 232 | 33 | 749 | 377 | 63 | 0.088 |
 Zhuo | 2018 | China | Asian | Lung cancer | 322 | 384 | 124 | 152 | 46 | 143 | 185 | 56 | 0.759 |
 Gong | 2017 | China | Asian | Colorectal cancer | 524 | 595 | 206 | 260 | 58 | 230 | 295 | 70 | 0.093 |
 Wei | 2019 | China | Asian | Breast cancer | 378 | 402 | 134 | 180 | 64 | 162 | 197 | 43 | 0.144 |
rs2762939 | |||||||||||||
 Holt a | 2009 | USA | Caucasian | Prostate cancer | 702 | 715 | 380 | 272 | 50 | 376 | 294 | 45 | 0.324 |
 Holt b | 2009 | USA | African | Prostate cancer | 114 | 67 | 29 | 48 | 37 | 13 | 32 | 22 | 0.824 |
 Wu | 2017 | China | Asian | Lung cancer | 426 | 445 | 160 | 192 | 74 | 156 | 220 | 69 | 0.553 |
 Holick | 2007 | UK | Caucasian | Prostate cancer | 568 | 539 | 319 | 212 | 37 | 300 | 196 | 43 | 0.173 |
 Reimers | 2015 | USA | Caucasian | Breast cancer | 921 | 970 | 514 | 348 | 59 | 560 | 353 | 57 | 0.889 |
rs4809960 | |||||||||||||
 Holick | 2007 | UK | Caucasian | Prostate cancer | 586 | 544 | 329 | 230 | 27 | 323 | 184 | 37 | 0.129 |
 Holt a | 2009 | USA | Caucasian | Prostate cancer | 697 | 693 | 432 | 220 | 45 | 387 | 260 | 46 | 0.794 |
 Holt b | 2009 | USA | African | Prostate cancer | 112 | 63 | 93 | 18 | 1 | 46 | 17 | 0 | 0.216 |
 Reimers | 2015 | USA | Caucasian | Breast cancer | 948 | 989 | 522 | 342 | 84 | 512 | 395 | 82 | 0.637 |
 Clendenen | 2015 | Sweden | Caucasian | Breast cancer | 733 | 1433 | 479 | 218 | 36 | 861 | 496 | 76 | 0.679 |
 Sadeghi | 2020 | Iran | Caucasian | Colorectal cancer | 220 | 243 | 119 | 95 | 6 | 105 | 119 | 19 | 0.062 |
 Yi | 2019 | China | Asian | Colorectal cancer | 787 | 800 | 415 | 311 | 61 | 468 | 290 | 42 | 0.736 |
rs6068816 | |||||||||||||
 Holick | 2007 | UK | Caucasian | Prostate cancer | 583 | 544 | 454 | 118 | 11 | 443 | 93 | 8 | 0.227 |
 Holt a | 2009 | USA | Caucasian | Prostate Cancer | 699 | 712 | 558 | 135 | 6 | 580 | 127 | 5 | 0.493 |
 Reimers | 2015 | USA | Caucasian | Breast cancer | 948 | 990 | 778 | 164 | 6 | 784 | 189 | 17 | 0.158 |
 Clendenen | 2015 | Sweden | Caucasian | Breast cancer | 733 | 1432 | 590 | 136 | 7 | 1149 | 264 | 19 | 0.389 |
 Yi | 2019 | China | Asian | Colorectal cancer | 787 | 800 | 342 | 354 | 91 | 362 | 348 | 90 | 0.645 |
 Qu | 2019 | China | Asian | Lung cancer | 345 | 351 | 160 | 155 | 30 | 131 | 178 | 42 | 0.116 |